trastuzumab

Overview

Trastuzumab, marketed under the brand name Herceptin, is a monoclonal antibody that specifically targets the human epidermal growth factor receptor 2 (HER2). This receptor is overexpressed in certain types of breast cancer and gastric cancer, making trastuzumab a critical therapeutic agent in the treatment of HER2-positive malignancies. By binding to HER2, trastuzumab inhibits the proliferation of tumor cells that overexpress this receptor, thereby exerting its antitumor effects through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and inhibition of downstream signaling pathways associated with cell growth and survival.

Focus of Latest Publications

Recent studies have explored various innovative approaches to enhance the efficacy of trastuzumab in cancer therapy. For instance, a study published in Chemistry investigated a self-propelled molecular rocket that could potentially overcome trastuzumab resistance in breast cancer by triggering ferroptosis and apoptosis, thereby improving treatment outcomes (PMID: 41789437). Another research article in Journal of Molecular Histology examined the synergistic effects of CD24 silencing combined with trastuzumab in HER2-positive breast cancer, suggesting that targeting oncogenic molecules like CD24 may enhance the therapeutic efficacy of trastuzumab (PMID: 42141178).

Additionally, a case report in Cancer Chemotherapy and Pharmacology highlighted the transfer of trastuzumab and pertuzumab into human breast milk, emphasizing the need for clinical data regarding drug exposure through breast milk (PMID: 42159752). This is particularly relevant for breastfeeding mothers undergoing treatment with these antibodies.

The combination of trastuzumab with other therapies has also been a focus of research. For example, the FDA approved the combination of pembrolizumab, trastuzumab, and platinum-based chemotherapy for the treatment of unresectable or metastatic HER2-positive gastric cancer (PMID: 41790455). Furthermore, a study in Phytomedicine reported that kaempferitrin could potentiate trastuzumab efficacy in HER2-positive gastric cancer by targeting Cyclooxygenase-2 to inhibit ERK signaling (PMID: 41797190).

Innovative drug delivery methods have also been explored, such as the conjugation of trastuzumab with magnetite nanoparticles to enhance intratumoral retention and efficacy in HER2-positive cells (PMID: 42011850). Moreover, a novel antibody-drug conjugate (ADC) combining trastuzumab with a topoisomerase I inhibitor demonstrated substantial antitumor activity in advanced solid tumors (PMID: 41856971).